All Stories

  1. Real-world outcomes of cilta-cel versus BCMA-targeting bispecific antibodies in relapsed/refractory multiple myeloma
  2. At the Crossroads of Lineage: Secondary Malignancies After CAR-Based Immunotherapy
  3. Trends in the design of FDA registrational randomised clinical trials in haematology and oncology: a 20-year cohort study
  4. Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial
  5. Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access
  6. Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access
  7. Chimeric antigen receptor T‐cell therapy for high‐grade B‐cell lymphoma NOS
  8. SGLT2 inhibitors and cardiovascular outcomes in patients with multiple myeloma and concomitant type 2 diabetes mellitus
  9. Estimation of Benefit to Bispecific Antibodies in US Patients with Lymphoma and Multiple Myeloma
  10. Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis
  11. CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma
  12. IgG replacement in multiple myeloma
  13. Relationships Among Health Insurance Literacy, Financial Toxicity, and Sociodemographic Factors in Patients With Cancer
  14. Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma
  15. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice
  16. Allogeneic Hematopoietic Stem Cell Transplant for Diffuse Large B-Cell Lymphoma: Evolving Role in the Era of CAR T-Cell Therapy
  17. Quality of the control arms in randomized trials of chronic lymphocytic leukemia enrolling in the USA: A systematic review
  18. Isolated CNS relapse of blastic plasmacytoid dendritic cell neoplasm
  19. Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity
  20. Primary Central Nervous System Lymphoma: Consensus, Controversies and Future Directions
  21. Change in 21‐gene Recurrence Score result after exposure to neo‐adjuvant endocrine therapy in patients with operable breast cancer
  22. Gone But Here
  23. Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma
  24. Hemostatic complications associated with ventricular assist devices
  25. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration
  26. Hanging Up the Gloves
  27. Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis
  28. Germ Cell Tumors with Malignant Somatic Transformation: A Mayo Clinic Experience
  29. Erratum
  30. Outcome disparities in colorectal cancer: a SEER-based comparative analysis of racial subgroups
  31. ASO Author Reflections: Role of Contrast-Enhanced Spectral Mammography in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic Therapy
  32. I Don’t Know
  33. Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission
  34. Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis
  35. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections
  36. Activity Of Imatinib In Clonal Extramedullary Myeloid Neoplasms With Eosinophilia
  37. Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy
  38. Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia—the Burden of Novelty
  39. Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma
  40. Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis
  41. Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma
  42. Necrobiotic xanthogranuloma: a 30-year single-center experience
  43. Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy
  44. Nivolumab-associated bone marrow necrosis
  45. A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma
  46. Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1 / PDGFRA rearrangement
  47. B-cell acute lymphoblastic leukemia with +der(1)t(1;19) (p13;p13.1) arising in the setting of CALR exon 9 mutated essential thrombocythemia
  48. Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy
  49. Cytomegalovirus reactivation is associated with a lower rate of early relapse in myeloid malignancies independent of in-vivo T cell depletion strategy
  50. Update on lung neuroendocrine tumors
  51. ERBB2 (HER2)Testing in Breast Cancer
  52. Radiation-induced breast cancer: the question of early breast cancer screening in Hodgkin's lymphoma survivors
  53. Unexpected Cardiac Masses
  54. Exploring the possibilities: airspace disease in the postallogeneic haematopoietic stem cell transplant period
  55. The Perils of Country Life: Human Monocytic Ehrlichiosis
  56. Maintaining sharp focus on a grainy film: miliary pattern in an elderly woman with acute respiratory failure
  57. Sudden cardiac arrest in a healthy young athlete
  58. Bilateral upper lobe opacification
  59. Diffuse unresolving pulmonary nodules in a patient with a history of cervical carcinoma
  60. A tick-borne illness unmasking asymptomatic Brugada syndrome
  61. Fatal Cytomegalovirus Disease after Combination Therapy with Corticosteroids and Rituximab for Granulomatosis with Polyangiitis
  62. Disseminated tuberculosis with tuberculous meningitis in an immunocompetent host
  63. Chronic rupture of the coronary sinus of Valsalva with pseudoaneurysm formation
  64. A cause to consider for chronic unresolving diarrhea
  65. Fulminant Wilson’s Disease Managed with Plasmapheresis as a Bridge to Liver Transplant
  66. Isolated neurocutaneous peripheral T cell lymphoma, NOS